Pricing Log in Create free account

Inhibikase Therapeutics, Inc. (IKT) vs Pyxis Oncology, Inc. (PYXS)

Inhibikase Therapeutics, Inc. and Pyxis Oncology, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Pyxis Oncology, Inc. are of similar size ($209.3M and $198.6M). Across the 9 metrics below, Inhibikase Therapeutics, Inc. leads on 8 and Pyxis Oncology, Inc. on 1.

Valuation

Metric IKT PYXS Biotechnology median
P/E n/m n/m 10.60
P/S 1,005.21 n/m 9.40
P/B 1.71 9.29 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 394.78 n/m 9.02
Earnings yield (28.67%) (84.94%) (32.88%)
Free cash flow yield (16.28%) (63.94%) (23.13%)

Profitability

Metric IKT PYXS Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (51.96%) (179.10%) (51.96%)
Return on assets (48.04%) (99.62%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IKT PYXS Biotechnology median
Revenue growth (TTM) 110.93% — 6.76%
EPS growth (last fiscal year) 57.76% 3.03% 29.88%
Revenue growth, 5-year CAGR (42.21%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IKT PYXS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.82 1.34 4.97
Net debt to EBITDA 3.44 0.82 1.01

Dividend

Metric IKT PYXS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IKT PYXS Biotechnology median
Market cap 209.30m 198.55m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack